CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

NCT03123783 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
140
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Apexigen America, Inc.

Collaborators